From Discovery to Patients: An Integrated Service for ADC Development

Feb 03, 2025

How Synaffix technology combined with Lonza’s end-to-end capabilities help tackle challenges with designing and developing best-in-class antibody-drug conjugates

Posted by Lonza

Antibody-drug conjugates (ADCs) hold immense potential in targeted therapies, but their complex design and development present significant challenges. By combining Synaffix’s GlycoConnect™ platform with Lonza’s end-to-end Ibex® Design ADC program, drug developers can streamline ADC development, enhancing stability, mitigating risks, and accelerating timelines from discovery to clinical production.

 

Find out more about these insights in our latest white paper by Peter Tjeerdsma, Head of Synaffix CMC and Regulatory Affairs, Lonza, and Raphael Frey, PhD, Director, Commercial Development, Bioconjugates, Lonza.

To schedule a meeting with our experts to discuss your needs, please contact your dedicated Business Development Specialist Holmsten Amanda Holmsten at amanda.holmsten@lonza.com

Download Attachment

See all Member News